4.1 Article

Outcomes and health care utilization of older patients with acute myeloid leukemia

Journal

JOURNAL OF GERIATRIC ONCOLOGY
Volume 12, Issue 2, Pages 243-249

Publisher

ELSEVIER
DOI: 10.1016/j.jgo.2020.07.002

Keywords

AML; Older patients; Health care utilization; Chemotherapy

Ask authors/readers for more resources

In older patients with acute myeloid leukemia (AML), intensive chemotherapy and hypomethylating agents are associated with significantly higher median overall survival compared to best supportive care. These treatments also lower the likelihood of spending a significant portion of survival time in the hospital. Despite most patients being referred to palliative care, a considerable percentage still die in the hospital setting.
Background: The incidence of acute myeloid leukemia (AML) in older patients is increasing, but practice guidelines balancing quality-of-life, time outside of hospital and overall survival (OS) are not established. Methods: We conducted a retrospective analysis comparing time outside hospital, OS and end-of-life care in AML patients >= 60 years treated with intensive chemotherapy (IC), hypomethylating agents (HMA) and best supportive care (BSC) in a tertiary hospital. Results: Of 201 patients diagnosed between 2005 and 2015, 54% received IC while 14% and 32% were treated with HMA and BSC respectively. Median OS was significantly higher in patients treated with IC and HMA compared with BSC (11.5 versus 16.2 versus 1.3 months; p < .0001). Median number of hospital admissions for the entire cohort was 3 (1-17) and patients spent <50% of their life after the diagnosis in the hospital setting. Compared to BSC, IC (HR 0.27, p < .0001) and HMA therapy (HR 0.16, p < .0001) were associated with the lower likelihood of spending at least 25% of survival time in hospital. Although 66% patients were referred to palliative care, the interval between referral to death was 24 (1-971) days and 46% patients died in the hospital. Conclusion: Older patients with AML, irrespective of treatment, require intensive health care resources, are more likely to die in hospital and less likely to use hospice services. Older AML patients treated with disease modifying therapy survive longer than those receiving BSC, and spend >50% of survival time outside the hospital. These data are informative for counselling older patients with AML. Crown Copyright (c) 2020 Published by Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available